This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pediatrics  • Bipolar Disorder  • Depression  • Mood Disorders  • Psychopharmacology  • Women's Health  • Pregnancy and Breast Feeding  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Mark Olfson, MD, MPH; Steven Marcus, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Several of the drugs used to treat bipolar disorder are known teratogens.¹ Maternal treatment with valproate sodium,² carbamazepine,³ and lithium⁴ are each associated with an increased risk of major congenital abnormalities.

In their recent study of maternal antidepressant treatment and neonatal outcomes, Oberlander and colleagues⁵ report that prenatal selective serotonin reuptake inhibitor (SSRI) exposure is associated with an increased risk of neonatal low birth weight and respiratory distress. The authors compare neonates born of mothers who received SSRIs during their pregnancies with those of depressed pregnant women who did not receive antidepressants. Although neither group of women received benzodiazepines or antipsychotic medications during their pregnancy, women treated with mood stabilizers were not excluded from the study. Because pregnant mothers treated with SSRIs are presumably more likely to receive mood stabilizers than those who are not treated with antidepressants, it is possible that in . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?